Nucleic Acid Therapeutics Initiative
  • Organisation
  • Science
  • Accelerator
    • Funding Platform
    • Funding Opportunities
    • Portfolio
  • Careers
  • News & Events

Preclinical Investigation of a Novel Target for siRNA Therapeutics in MASH

Posted on March 2, 2026 by Vanessa Tay
← Facilitating skin and skin cell penetration by therapeutic oligonucleotides using lipid modifications
Splice-Switching Oligonucleotide (SSO) for Restoration of Functional Protein in a Rare Metabolic Disease →
Email
LinkedIn
Nucleic Acid Therapeutics Initiative (NATi)
31 Biopolis Way, Nanos #09-01, Singapore 138669
© 2026 Nucleic Acid Therapeutics Initiative | Privacy Policy | Terms and Conditions
Nucleic Acid Therapeutics Initiative
Join OurMailing List